✦ LIBER ✦

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma

✍ Scribed by Han Chong Toh; Pei-Jer Chen; Brian I. Carr; Jennifer J. Knox; Sharlene Gill; Peter Ansell; Evelyn M. McKeegan; Barry Dowell; Michelle Pedersen; Qin Qin; Jiang Qian; Frank A. Scappaticci; Justin L. Ricker; Dawn M. Carlson; Wei Peng Yong

Book ID: 112067289
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 958 KB
Volume: 119
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.27758

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6517 International phase 2 trial of ABT-

6517 International phase 2 trial of ABT-869 in patients with advanced hepatocellular carcinoma (HCC)

✍ Toh, H.C.; Chen, P.; Knox, J.J.; Gill, S.; Carlson, D.M.; Qian, J.; Ricker, J.L. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Phase 2 trial of linifanib (ABT-869) in

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

✍ Nizar M. Tannir; Yu-Ning Wong; Christian K. Kollmannsberger; Marc S. Ernstoff; D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 322 KB

Phase 2 study of erlotinib in patients w

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

✍ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti

Phase 2 trial of concurrent bevacizumab

Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

✍ Buijs, Manon; Reyes, Diane K.; Pawlik, Timothy M.; Blackford, Amanda L.; Salem, 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB

Regorafenib for patients with previously

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial

✍ Tim Eisen; Heikki Joensuu; Paul D Nathan; Peter G Harper; Marek Z Wojtukiewicz; 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 231 KB

Phase I trial of sorafenib in combinatio

Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

✍ Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Ham 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 359 KB